cis-8-Octadecenoic Acid
(Synonyms: cis-8-Octadecenoate) 目录号 : GC41585A monounsaturated fatty acid
Cas No.:5684-71-9
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
cis-8-Octadecenoic acid is a monounsaturated fatty acid and an isomer of oleic acid , trans-vaccenic acid , trans-petroselinic acid , and cis-petroselinic acid . It has been found in partially hydrogenated vegetable oil and milk fat.[1]
Reference:
[1]. Yoshinaga, K., Asanuma, M., Mizobe, H., et al. Characterization of cis- and trans-octadecenoic acid positional isomers in edible fat and oil using gas chromatography-flame ionisation detector equipped with highly polar ionic liquid capillary column. Food Chem. 160, 39-45 (2014).
| Cas No. | 5684-71-9 | SDF | |
| 别名 | cis-8-Octadecenoate | ||
| 化学名 | 8Z-octadecenoic acid | ||
| Canonical SMILES | CCCCCCCCC/C=C\CCCCCCC(O)=O | ||
| 分子式 | C18H34O2 | 分子量 | 282.5 |
| 溶解度 | 30mg/mL in DMSO, or in DMF | 储存条件 | Store at -20°C |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 3.5398 mL | 17.6991 mL | 35.3982 mL |
| 5 mM | 0.708 mL | 3.5398 mL | 7.0796 mL |
| 10 mM | 0.354 mL | 1.7699 mL | 3.5398 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Incorporation of trans-8- and cis-8-Octadecenoic Acid isomers in human plasma and lipoprotein lipids
Lipids 1989 Jan;24(1):61-9.PMID:2747432DOI:10.1007/BF02535266.
Mixtures of deuterium-labeled trans-8, cis-8 and cis-9-octadecenoic acids (8t-18:1, 8c-18:1, 9c-18:1) were fed as triglycerides (TG) to two adult male subjects. Blood samples were collected sequentially over a 48-hour period. Plasma and lipoprotein lipids were separated by thin layer chromatography and analyzed by gas chromatography-mass spectroscopy. Results indicate (i) absorption of the 8t- and 8c-18:1 isomers were similar to 9c-18:1; (ii) the 8t-18:1 isomer was cleared approximately 30% faster than 9c-18:1 from plasma TG; (iii) cholesterol ester samples contained 8.4 times less 8t-18:1 than 9c-18:1; (iv) incorporation at the 1-acyl phosphatidylcholine (PC) position was higher for 8t-18:1 and 8c-18:1 (2.2 and 1.7 times) than for 9c-18:1; and (v) discrimination at the 2-acyl PC position was 4.6-fold against 8t-18:1 and 1.3-fold against 8c-18:1 compared with 9c-18:1. Discrimination against uptake of the delta-8 isomers in both neutral and phospholipid classes suggests that both 8t- and 8c-18:1 may be preferentially oxidized relative to 9c-18:1. Except for triglycerides, data for each of the lipid classes from total plasma and individual lipoprotein samples were similar. These data indicate that differences for incorporation and turnover of the 8t- and 8c-18:1 isomers relative to 9c-18:1 are not substantially influenced by the lipoprotein classes. The maximum isotopic enrichment detected in the chylomicron triglycerides fractions was 60%, which indicates that a substantial amount of endogenous triglycerides was mobilized during absorption of the deuterated fats.
Miracle fruit seed as a potential supplement for the treatment of learning and memory disorders in Alzheimer's disease
Front Pharmacol 2023 Jan 11;13:1080753.PMID:36712676DOI:10.3389/fphar.2022.1080753.
Currently, the treatment of Alzheimer's disease (AD) is still at the stage of symptomatic treatment due to lack of effective drugs. The research on miracle fruit seeds (MFSs) has focused on lipid-lowering and antidiabetic effects, but no therapeutic effects have been reported in AD. The purpose of this study was to provide data resources and a potential drug for treatment of AD. An AD mouse model was established and treated with MFSs for 1 month. The Morris water maze test was used to assess learning memory function in mice. Nissl staining was used to demonstrate histopathological changes. MFSs were found to have therapeutic implications in the AD mouse model, as evidenced by improved learning memory function and an increase in surviving neurons. To explore the mechanism of MFSs in treating AD, network pharmacological approaches, Gene Ontology (GO), Kyoto Encyclopedia of Genes and Genomes (KEGG), and molecular docking studies were carried out. Based on the network pharmacology strategy, 74 components from MFS corresponded to 293 targets related to the AD pathology. Among these targets, AKT1, MAPK3, ESR1, PPARG, PTGS2, EGFR, PPARA, CNR1, ABCB1, and MAPT were identified as the core targets. According to the relevant number of core targets, cis-8-Octadecenoic Acid, cis-10-octadecenoic acid, 2-dodecenal, and tetradecane are likely to be highly correlated with MFS for AD. Enrichment analysis indicated the common targets mainly enriched in AD and the neurodegeneration-multiple disease signaling pathway. The molecular docking predictions showed that MFSs were stably bound to core targets, specifically AKT1, EGFR, ESR1, PPARA, and PPARG. MFSs may play a therapeutic role in AD by affecting the insulin signaling pathway and the Wnt pathway. The findings of this study provide potential possibilities and drug candidates for the treatment of AD.